- Open Access
Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2
© El Abd et al; licensee BioMed Central Ltd. 2011
- Received: 4 June 2011
- Accepted: 5 August 2011
- Published: 5 August 2011
Anti HCV vaccine is not currently available and the present antiviral therapies fail to cure approximately half of the treated HCV patients. This study was designed to assess the immunogenic properties of genetically conserved peptides derived from the C-terminal region of HVR-1 and test their neutralizing activities in a step towards developing therapeutic and/or prophylactic immunogens against HCV infection. Antibodies were generated by vaccination of goats with synthetic peptides derived from HCV E2. Viral neutralizing capacity of the generated anti E2 antibodies was tested using in vitro assays. Goats immunized with E2 synthetic peptides termed p412 [a.a 412-419], p430 [a.a 430-447] and p517 [a.a 517-531] generated high titers of antibody responses 2 to 4.5 fold higher than comparable titers of antibodies to the same epitopes in chronic HCV patients. In post infection experiments of native HCV into cultured Huh7.5 cells anti p412 and anti p 517 were proven to be neutralizing to HCV genotype 4a from patients' sera (87.5% and 75% respectively). On the contrary anti p430 exhibited weak viral neutralization capacity on the same samples (31.25%). Furthermore Ab mixes containing anti p430 exhibited reduced viral neutralization properties. From these experiments one could predict that neutralization by Abs towards different E2-epitopes varies considerably and success in the enrichment of neutralization epitope-specific antibodies may be accompanied by favorable results in combating HCV infection. Also, E2 conserved peptides p517 and p412 represent potential components of a candidate peptide vaccine against HCV infection.
- Hepatitis C virus (HCV)
- anti E2 antibodies
- neutralizing antibodies
- In vitro culture model for HCV
- candidate peptide vaccine for HCV
Hepatitis C Virus (HCV) is a global health problem that affects almost 3% of the world's population  and not less than 15% of the Egyptian population . Individuals with chronic HCV infection usually remain asymptomatic and undiagnosed for decades before chronic hepatitis leads to severe fibrosis and cirrhosis, hepatic failure, or hepatocellular carcinoma [3–7]. These long-term complications made HCV one of the leading emerging infectious diseases worldwide. The current antiviral regimen, a combination of pegylated interferon α and ribavirin, is curative in about half of treated patients depending on the viral and/or host factors. Additionally, this regimen is expensive, requires prolonged therapy, sometimes with serious side effects and only a fraction of those with chronic HCV infections meet the criteria for treatment .
Viral proteins are recognized as non-self by the host's immune system and induce the production of antibodies. During the natural course of infection, a large number of antibodies are produced. The vast majority of antibodies induced have no antiviral activity, either because they are elicited by degraded or incompletely processed proteins released from dying cells or because they are directed against epitopes that do not play any role in the virus entry process "non-neutralizing antibodies". A small proportion of antibodies termed "neutralizing antibodies" are able to target exposed epitopes of the viral structural proteins and neutralize the infectious virus by preventing or controlling viral infection [9, 10]. During the chronic phase of HCV infection, most HCV-infected patients develop high-titer of antibodies. Paradoxically, these antibodies were not able to control HCV infection which may be attributed to the generation of non-neutralizing HCV-specific antibodies that compete with neutralizing Abs and reduce their effectiveness. Such antibodies have been reported in other viral infections in which highly immunogenic non-neutralizing epitopes mislead the humoral immune response contributing to viral escape from neutralization . Several observations support the hypothesis that neutralizing antibodies may help control HCV replication [12, 13].
Synthetic peptide based vaccines were shown to generate specific Abs capable of neutralizing HCV infections [14, 15]. In the present study, we utilized large scale multiple sequence alignment of E2 to design genetically conserved peptides from viral envelop proteins (particularly among type 4 isolates predominant in Egypt). The aim of this work is to develop monospecific polyclonal Abs in caprines against the 3 chosen conserved peptides derived from E2 glycoprotein and to test the immunogenic and viral neutralizing properties of each Ab using assays depending on blocking of viral infectivity to hepatoma cell line. Based on the obtained results, p412 and p517 represent candidate peptides for further assessment as potential therapeutic/prophylactic immunogens.
This research was approved by the Review Board of National Research Center, Egypt
Design and synthesis of HCV E2 conserved peptides
Three peptides were designed and synthesized as previously described . Peptides were all derived from the C-terminal region of HVR-1 and designated p412 [a.a 412-419], p430 [a.a 430-547] and p517 [a.a 517-531].
Immunization of caprines, production and purification of polyclonal antibodies
Six goats were immunized with either of the synthetic peptides p412, p 430 or p517 (2 animals for each peptide). Two goats were injected with 2 ml saline solution at the same time intervals of immunization protocol to serve as controls. The immunizing doses/goat were 1.5 mg of the peptide. Each linear peptide was emulsified with equal volume of Freund's complete adjuvant and was injected subcutaneously in three different sites within the same animal. On days 15 and 28, blood samples were collected and then each goat was reimmunized with a second booster dose of the same peptide emulsified with equal volume of Freund's incomplete adjuvant. The goats were sacrificed after 96 days from the last injection and the blood was collected to quantify the titer of relevant immunoglobulins. Caprine IgG was purified out following a procedure described by Mckinney and Parkinson, . Briefly, IgG purification was carried out in two steps, step 1 involves elimination of albumin and other non IgG proteins via precipitation with Caprilyic acid (Octanoic acid; Riedel-DE HAEN AG, Seelze-Hannover, Germany). While step 2 includes further purification of IgG fractions using ammonium sulphate cut as reported by Mohanty and Elazhary .
Efficacy and specificity of purified caprine IgGs towards the relevant E2 antigens in HCV infected human sera
Western blot analysis was used to detect circulating E2 proteins and/or relevant epitopes on HCV virions using the purified caprine antibodies as previously described [16, 19, 20]. In brief, strips with HCV serum proteins were washed 3 times and incubated with diluted first anti p412 Ab (1:100 in PBS-0.3% T20) at room temperature for 2 h. After 3 washes, strips were incubated with anti-caprine IgG peroxidase labeled second Ab (KPL, Gaithersburg, USA) diluted in 1: 5000 PBS-0.3% T for 2 h at room temperature. Visualization of bands on the nitrocellulose membrane was done by incubating the strips with 0.01 M PBS, pH 7.4 containing 50 mg, peroxidase specific substrate, diaminobenzedine DAB (Sigma; Deisenhofen, Germany) and 100 μl of 3% hydrogen peroxide.
Establishment of cell culture system infected with HCV
Human well differentiated hepatocellular carcinoma cell line Huh7 was modified to produce a more efficient cell line Huh7.5 a generous gift from Charles Rice (The Rockefeller University, USA). The cells were obtained under Material Transfer Agreement (MTA# 642 to Dr. Mostafa K. El Awady 2007). Huh7.5 cells were used for HCV infection experiments and assessment of viral replication. Huh7.50 cells were cultured and infected with HCV particles according to protocols described by Seipp et al.,  and Song et al.,. Assessment of the successful viral infection in Huh7.5 cells throughout the culture duration was confirmed at the transcriptional level by Reverse Transcription Polymerase Chain Reaction (RT-PCR) amplification of HCV RNA and at the translational level by SDS-PAGE of cell lysates followed by Western blotting to determine the de novo synthesis of non structural proteins e.g NS5A. Western blot was done as described before except that the membrane was incubated with diluted mouse monoclonal anti-NS5A (Ab, Abcam; Cambridge, UK) (1: 200 in PBS-0.3% T) at room temperature for 2 h and after the 3 washes, the membrane was incubated for 2 h at room temperature with diluted peroxidase labeled anti-mouse IgG Ab (1: 1000 in PBS-0.3% T). For Reverse transcription -PCR (RT-PCR), retrotranscription was performed in 25 μl reaction mixture containing 20 units of AMV reverse transcriptase (Clonetech, USA) with 400 ng of total cellular RNA as template, 40 units of RNAsin Clontech, USA), a final concentration of 0.2 mmol/l from each dNTP (Promega, Madison, WI, USA) and 50 pmol of the reverse primer P1. The reaction was incubated at 42°C for 60 min. and denatured at 98°C for 10 min. Amplification of the highly conserved 5'-UTR sequences was done using two rounds of PCR with 2 pairs of nested primers. The first round amplification was done in 50 μl reaction containing 50 pmol from each of P2 forward primers and P3 reverse primers, 0.2 mmol/l from each dNTP, 10 μl from RT reaction mixture as template and 2 units of Taq DNA polymerase (Promega, USA) in 1 × buffer supplied with the enzyme. The thermal cycling protocol was as follows: 1 min at 94°C, 1 min at 55°C and 1 min at 72°C for 30 cycles. The second round amplification was done as the first round, except for use of the nested reverse primer P4 and forward primer P5 at 50 pmol each. A fragment of 172 bp was identified in positive samples. Primer sequences are as follows: P1: 5'ggtgcacggtctacgagacctc 3'; P2: 5' aactactgtcttcacgcagaa 3'; P3: 5' tgctcatggtgcacggtcta 3'; P4: 5' actcggctagcagtctcgcg 3'; P5: 5' gtgcagcctccaggaccc 3'
Testing the immunoreactivity of caprine anti p412 antibody with intracellular E2 protein
Intracellular expression of E2 antigen in infected Huh7.5 cells was confirmed via 3 independent immuno assays; namely western blotting, intracellular immunosaining and FACS analysis. Western blotting was performed as previously mentioned. Intracellular HCV immunostaining assay was achieved as follows: Cells (either infected or non infected) were grown in 6 well cell culture plates (Greiner Bio-one, Germany) for 48 h to semi-confluency. Prior to staining, cells were washed with PBS and immunostained according to a procedure described by Harlow and Lane . Briefly, cells were fixed with 4% paraformaldehyde solution in PBS for 10 min at room temperature and then washed twice with PBS. Fixed cells were permeabilized by incubation in 0.2% TritonX-100 in PBS for 15 min, followed by washing 3 times with PBS. Blocking the non-specific antibody binding sites was done by incubating cells for 10 min in blocking buffer (PBS-1% BSA). Cells were incubated with anti p412 Ab at dilution 1/200 in PBS -1% BSA for 1 h at room temperature. Cells were then washed 3 X with PBS, 10 min each wash. Horseradish peroxidase conjugated anti-caprine IgG (KPL, Gaithersburg, USA) at dilution 1/2000 in PBS-1% BSA was added to the monolayer cells and incubated for 1 h at room temperature. Colored foci were revealed by incubating the cells with 0.01 M PBS, pH 7.4 containing 50 mg, peroxidase specific substrate, diaminobenzedine (Sigma; Deisenhofen, Germany) and 100 μl of 3% hydrogen peroxide and stopped after 10 min of incubation with distilled water. The distinct colored foci were examined and some positive and negative fields were photographed on phase contrast microscope (Olympus IX70, USA). To further analyze the immunoreactive properties of caprine anti p412 Ab antibody with the E2 antigen localized on the surface of Huh7.5 cells, FACS analysis of HCV E2 antigen was performed on surface of infected Huh7.5 cells as follows: cells were infected with a pool of high HCV viral loads. The plates were incubated at 37°C with media change every two days. After one week incubation, media were aspirated and cells were washed three times with PBS, collected then centrifuged and supernatants were removed. Cell pellets were washed 4 times with PBS. Surface labeling was performed by indirect immuno-fluorescence, where cells were incubated with anti p412 Ab (at dilution 1/200 in PBS) for 1 h at 4°C, and washed 4 times with PBS. Fluorescein isothiocyanate (FITC) labeled anti Caprine IgG (KPL, Gaithersburg, USA) at dilution 1: 2000 in PBS was added to the cells for 30 min at 4°C. Cells were washed 3 times with PBS containing 1% normal caprine serum to decrease nonspecific fluorescence, then cells were suspended in 500 μl PBS and analyzed with BD FACS Calibur™ Flow Cytometer (Becton Dickinson, USA). Mean fluorescence intensities were determined using cell Quest software (Becton Dickinson, USA).
Testing the viral neutralizing capacity of caprine anti E2 antibodies
Viral neutralizing activity of caprine anti E2 antibodies was studied using HCV infected Huh7.5 and pursuing the viral replication via RT-PCR amplification. In order to study the antibody mediated neutralization, different concentrations of the generated E2 antibodies were pre-incubated with a pool of 10 HCV genotype 4a infected sera with viral loads ranging from 9 × 105-1.5 × 106 copies/ml prior to incubation with Huh7.5 cells. Viral binding/entry to cells was detected by nested RT-PCR. In a 1.5 ml tube, HCV positive sera that were pre-diluted with FCS free media (1: 50) was incubated with serial dilutions of caprine anti E2 antibodies from 150 μg/ml to 2.5 μg/ml in a final volume of 1 ml FCS-free DMEM. Pooled HCV positive sera as well as HCV negative (negative HCV RNA and IgG Abs) were diluted 1:50 in 1 ml FCS-free DMEM and used for infection assays as positive and negative controls respectively. All tubes were then incubated overnight at 4°C before supplementation to cells. Huh7.5 cells (200,000 cells/well) were grown to semi-confluence in DMEM supplied with 10% FCS, 1% Penicillin-Streptomycin and 0.1% fungizone in 6 well plates for 48 h. The media were aspirated, then cells were washed twice with FCS-free medium and inoculated with 1 ml of the previously incubated sera-antibody mix. For each assay, two wells were left without serum inoculation (supplied only with DMEM) to serve as reagent negative controls. After 90 minutes at 37°C in 5% CO2, 1 ml DMEM containing 10% FCS was added to each well. On the next day media were aspirated and cells were washed three times with PBS to get rid of the remaining sera-antibody mix, replaced with fresh medium (DMEM-10% FCS) and cells were further incubated for 24 h at 37°C. On the third day, media were aspirated and 500 μl of (4 M guanidinium thiocyanate/0.5% sarcosyl) was added to each well. Extraction of total cellular RNA was done as described by El Awady et al . Amplification of of HCV RNA was performed using 5'UTR specific nested primers as stated above.
Effect of HCV viral load on infectivity of Huh7.5 cultured cells and on the blocking activity of the generated caprine antibodies
To test whether the viral load in HCV positive samples affects viral entry into Huh7.5 cells or the blocking activity of the generated caprine antibodies, viral loads were quantified in 20 samples prior to application in the infection experiments. A statistical correlation was made between viral loads in each sample and the blocking activity of the generated caprine antibodies. T- Test was conducted to correlate both parameters. Testing the blocking of viral entry into hepatoma cells by different combinations of caprine anti E2 antibodies
To test the possible molecular and/or steric interference of a combination of two caprine anti E2 antibodies on blocking of viral entry into cultured Huh7.5 cells, a pool of 10 HCV 4a positive sera were pre-incubated with the following 3 Ab combinations (anti p412 + anti p430), (anti p412 + anti p517) and (anti p430+ anti p517) prior to infection of cells. Viral RNA was extracted and subjected to intracellular viral evaluation using both nested RT-PCR as previously described and quantitatively by Real Time PCR (Qiagen, CA USA), where a single-tube real time RT-PCR assay was performed for the quantification of the 5' NCR of HCV by using Taqman technology [Roche Molecular Diagnostics Systems].
All statistical analyses were performed using the SPSS 9.0 statistical software program. The difference is considered statistically significant when p ≤ 0.05.
Specificity of purified caprine IgG in detection of circulating E2 antigen in HCV positive sera
Evaluation of Huh7.5 hepatoma cells' support of HCV replication in vitro
Testing the immuno-reactivity of caprine anti E2 Abs with Huh7.5 expression of E2 antigen
Three approaches were followed to test this immunoreactivity, namely western blot, immunocytochemistry and FACS analysis.
a) Western blot analysis of infected Huh7.5 cells using caprine anti p412 Ab to detect intracellular viral E2 antigens.
b) Intracellular HCV immunostaining assay
c) Flow Cytometric analysis of HCV E2 expression on surface of Huh7.5 cells using caprine anti p412 Ab.
Effect of caprine anti E2 Abs on HCV 4a RNA replication in Huh7.5 cells
a) Titration of Ab concentration achieving viral neutralization
b) To test whether caprine Abs towards different E2 epitopes elicit the same blocking activity on HCV replication in Huh7.5 cells, the latter were infected separately with 20 HCV 4a positive sera, with varying values of viral loads, in absence and presence of 10 μg/ml of either caprine anti p430, anti p517 or anti p412 purified Abs in the culture medium. Intracellular HCV RNA was extracted, nested RT-PCR amplified and resolved on 2% agarose gel. The results show that this method exhibited 80% efficiency of viral infection into Huh7.5 cells. Furthermore, anti p517 and anti p412 Abs exhibited the highest potency in blocking of viral replication in cells (75% and 87.5% respectively) as compared with anti p430 Ab (31.5%). These results were confirmed by findings displayed in Figure 9 produced after infecting Huh7.5 cells with a pool of HCV 4a positive sera and incubation with the 3 tested caprine Abs at decreasing concentrations of purified Abs (10 - 2.5 μg/ml). Figure 9 showed that the tested range of anti p517 and anti p412 Ab concentrations did induce total inhibition of intracellular viral replication, whereas anti p430 Ab failed to induce inhibition of HCV replication at concentrations below 10 μg/ml.
Interference exerted by non neutralizing Abs on viral neutralization
Three synthetic peptides were mapped to conserved epitopes within the carboxy terminal region of the HVR-1 of E2 protein. These immunogenic peptides were selected to be genetically conserved at least among viral subtypes infecting the local population, predominantly 4a. The peptide p430 showed 88% homology with HCV genotype 4a while p517 and p412 showed 93% and 100% homology respectively . The present data demonstrate that immunization of caprines with these peptides can elicit significant humoral responses and the generated Abs were able to recognize relevant epitopes, either as the free soluble antigen or on surface of HCV particles in sera of chronically infected patients, thus suggesting its usefulness as specific diagnostic reagents. The expression of E2 related peptide in western blots at 58 kDa upon treatment with caprine IgG only in HCV positive sera confirms earlier data  that it represents a deglcosylated E2 protein and suggests the presence of immunodominant conserved epitopes within the E2 gp which encompass motifs of several linear epitopes. We have recently shown that these linear epitopes stimulated humoral and cellular responses in caprines  and in mice . The observed immunoreactivity of these peptides with human IgG in HCV positive patients suggest that those E2 epitopes are immunogenic in humans, a hypothesis awaiting confirmation in future testing of healthy volunteers.
Hepatoma cells Huh7.5 posses CD81 receptor, a strong candidate receptor that enables HCV particles to bind to cells [26, 27]. We have clearly demonstrated that direct infection of Huh7.5 cells from HCV positive sera resulted in viral entry into the cells as indicated by considerable quantities of intracellular viral RNA genomic and antigenomic strands throughout the duration of cell culture. The viral entry was followed by de novo synthesis of both structural and non structural proteins E2 and NS5A suggesting that these cells support the de novo expression of viral proteins. The appearance of two immunogenic peptides 70 and 115 kDa in infected Huh7.5 cells represent E2 protein and E1/E2 dimer respectively, thus supporting previous reports [28–30]. Since NS5A is not detectable in HCV positive sera its detection in cell lysates represents a marker for efficient infection and intracellular HCV replication . Infected Huh7.5 cells were able to shed virus into culture medium, where the later could efficiently infect naïve Huh7.5 cells (results not shown). Infection of cells in vitro with HCV from a variety of sources can at least demonstrate the infectivity of the virus making these systems useful in evaluating drugs for antiviral activity or inhibition of HCV replication [19, 22, 32]. Transfection with synthetic full-length or near-full-length HCV RNA has the drawback that the RNA used for transfection is homogenously synthesized containing well defined sequence whereas in cases of natural infection with the whole viral particles several quasispecies of different magnitudes of infectivity could be coexisting, thus mimicking the in vivo infections of HCV. Other disadvantage of synthetic subgenomic virus transfection could be the absence of one or more non structural genes, which does not allow assembly of infectious viral particles as demonstrated by failure to infect chimpanzees . When the full viral genome was put in frame downstream a strong promoter, it is obviously expected that the replication and the regulation of expression of viral proteins will not take place under viral regulatory elements. Besides, the system has the limitation of being restricted to single quasispecies and the chances of variant production, mimicking the natural infection, are poor.
In the present study we thought that not all antibodies raised against conserved peptides are neutralizing. Although caprine anti p430 Ab did not interfere with HCV entry at concentrations below 10 μg/ml, caprine anti p412 and p517 Abs, on the other hand, were able to block HCV entry into cells at concentration as low as 2.5 μg/ml, suggesting that the later two Abs are potentially neutralizing. The reason why high Ab concentrations did not neutralize the virus could attributed to aggregation and inability to bind to their corresponding epitopes,  a phenomenon previously referred to as zone tolerance between the amounts of Ab relative to its Ag. In general, the current data confirm our earlier results that caprine anti p412 and anti p517 Abs could bind HCV in immuncapture experiments while anti p430 Ab could not . This agrees to earlier findings of Zhang et al.,  who mapped two epitopes within a short segment of E2: epitope I, at amino acids 412-419 and epitope II, at amino acids 434-446 and demonstrated that epitope I, but not epitope II, was involved in virus neutralization under their experimental conditions, using HCV genotype 2a. The region encompassing amino acids 432-447 can be recognized by at least three monoclonal antibodies. Hsu et al.,  using HCV pseudoparticle assay demonstrated that these MAbs were involved in viral neutralization. Knowing that genotypes 1, 4, 5, and 6 are serologically more closely related to each other than to genotypes 2 and 3 , the possibility that epitope II in various genotypes is associated with neutralization could not be excluded. Needless to say, assay systems and virus genotypes used in different studies may explain different outcomes of neutralization studies. To examine the possibility that anti p430 Ab displays a steric/or masking effect on the viral neutralization properties exerted by either anti p412 or anti p517 Abs, we performed viral neutralization assays in presence of a variety of Ab mixes. The current results clearly demonstrate that anti p430 Ab displayed a negative effect on the other two Abs so that it demolished their neutralizing activities, while a mixture of anti p412 and anti p517 exhibited potent viral neutralization properties either as singles or in combinations. These in vitro experiments perhaps explain the observed failure of viral neutralization and/or clearance in chronic HCV patients despite the presence of a pool of E2 Abs in their sera. These findings suggest that caprine anti p517 and anti p412 Abs may have been interfered by anti p430 Ab either at the level of viral adsorption and/or entry into cells thus leading to failure of inhibition of HCV replication inside the cells. This conclusion confirms the hypothesis made by von Hahn et al., , Stamataki et al.,  and Zhang et al.,  that co-existence of non neutralizing and neutralizing Abs may lead to hindrance of neutralizing activity in chronic HCV patients.
Efficiency of blocking intracellular viral replication by caprine anti E2 epitopes
Groups of HCV samples*
Number of samples (n = 20)
Viral load copies/ml (Mean ± S.D)
Successfully the cells
517,646 - 1,952,184
Successfully with anti p430
313,992 - 940,408
Successfully with anti p517
510,059 - 1,694,683
Successfully with anti p412
497,516 - 1,985,120
Liver transplant recipients mostly suffer re-infection of grafts shortly after transplantation. One approach to control re-infection is the combined use of specific antiviral together with HCV-specific antibodies . So we anticipate that the long term benefit of this study will be to generate fully human monoclonal antibodies against HCV E2 synthetic peptides derived from genetically conserved regions and use as supplement to IFN based therapy in post transplants of HCV positive patients. One could also predict that exclusive administration of neutralizing epitopes would be rather adequate to confer prophylaxis against early exposure to HCV infection. In conclusion, taking together the results of humoral immunity and cellular responses suggest that p412 and p517 peptides described herein are potential candidates for designing a prophylactic and/or therapeutic vaccine against HCV for further clinical studies.
This work was partially funded through the Science and Technology Development Fund (STDF), Egypt-grant no. 894" to Dr. Ashraf Tabll and by Misr El-khair foundation to Dr. Mostafa El-Awady. Authors thank Mr. M. Hasan for assistance.
- Alte MJ: Epidemiology of Hepatitis C virus infection. World J Gastroenterol 2007,13(17):2436-2441.View ArticleGoogle Scholar
- Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107View ArticlePubMedGoogle Scholar
- Kenny-Walsh E: Clinical outcomes after Hepatitis C infection from contaminated anti-d immune globulin. Irish hepatology research group. N Engl J Med 1999,340(16):1228-1233. 10.1056/NEJM199904223401602View ArticlePubMedGoogle Scholar
- Thomas DL, Astemborski J, Rai RM, et al.: The natural history of Hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000,284(4):450-456. 10.1001/jama.284.4.450View ArticlePubMedGoogle Scholar
- Freeman AJ, Dore GJ, Law MG, et al.: Estimating progression to cirrhosis in chronic Hepatitis C virus infection. Hepatology 2001,34(4 (Part 1)):809-816. 10.1053/jhep.2001.27831View ArticlePubMedGoogle Scholar
- Wiese M, Grungreiff K, Guthoff W, et al.: Outcome in a Hepatitis C (genotype 1b) single source outbreak in germany--a 25-year multicenter study. J Hepatol 2005,43(4):590-598. 10.1016/j.jhep.2005.04.007View ArticlePubMedGoogle Scholar
- Ferenci P, Ferenci S, Datz C, et al.: Morbidity and mortality in paid austrian plasma donors infected with Hepatitis C at plasma donation in the 1970s. J Hepatol 2007,47(1):31-36. 10.1016/j.jhep.2007.01.023View ArticlePubMedGoogle Scholar
- Manns MP, Wedemeyer H, Cornberg M: Treating viral Hepatitis C: Efficacy, side effects, and complications. Gut 2006,55(9):1350-1359. 10.1136/gut.2005.076646PubMed CentralView ArticlePubMedGoogle Scholar
- Hangartner L, Zellweger RM, Giobbi M, et al.: Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J Exp Med 2006,203(8):2033-2042. 10.1084/jem.20051557PubMed CentralView ArticlePubMedGoogle Scholar
- Hangartner L, Zinkernagel RM, Hengartner H: Antiviral antibody responses: The two extremes of a wide spectrum. Nat Rev Immunol 2006, 6: 231-243. 10.1038/nri1783View ArticlePubMedGoogle Scholar
- Zhang P, Wu CG, Mihalik K, et al.: Hepatitis C virus epitope-specific neutralizing antibodies in igs prepared from human plasma. Proc Natl Acad Sci USA 2007,104(20):8449-8454. 10.1073/pnas.0703039104PubMed CentralView ArticlePubMedGoogle Scholar
- Witteveldt J, Evans MJ, Bitzegeio J, et al.: CD81 is dispensable for Hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009,90(Part 1):48-58. 10.1099/vir.0.006700-0PubMed CentralView ArticlePubMedGoogle Scholar
- Bankwitz D, Steinmann E, Bitzegeio J, et al.: Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010,84(11):5751-5763. 10.1128/JVI.02200-09PubMed CentralView ArticlePubMedGoogle Scholar
- Firbas C, Jilma B, Tauber E, et al.: Immunogenicity and safety of a novel therapeutic Hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006,24(20):4343-4353. 10.1016/j.vaccine.2006.03.009View ArticlePubMedGoogle Scholar
- Klade CS, Wedemeyer H, Berg T, et al.: Therapeutic vaccination of chronic Hepatitis C nonresponder patients with the peptide vaccine ic41. Gastroenterology 2008,134(5):1385-1395. 10.1053/j.gastro.2008.02.058View ArticlePubMedGoogle Scholar
- El-Awady MK, Tabll AA, El-Abd YS, et al.: Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J 2009,6(66):. 10.1186/1743-422X-6-66Google Scholar
- McKinney MM, Parkinson A: A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Methods 1987,96(2):271-278. 10.1016/0022-1759(87)90324-3View ArticlePubMedGoogle Scholar
- Mohanty JG, Elazhary Y: Purification of IgG from serum with caprylic acid and ammonium sulphate precipitation is not superior to ammonium sulphate precipitation alone. Comp Immunol Microbiol Infect Dis 1989,12(4):153-160. 10.1016/0147-9571(89)90064-7View ArticlePubMedGoogle Scholar
- El-Awady MK, Tabll AA, El-Abd YS, et al.: HepG2 cells support viral replication and gene expression of Hepatitis C virus genotype 4 in vitro. World J Gastroenterol 2006,12(30):4836-4842.PubMed CentralPubMedGoogle Scholar
- Tabll AA, Khalil SB, El-Shenawy RM, et al.: Establishment of hybrid cell lines producing monoclonal antibodies to a synthetic peptide from the E1 region of the Hepatitis C virus. J Immunoassay Immunochem 2008,29(1):91-104.View ArticlePubMedGoogle Scholar
- Seipp S, Mueller HM, Pfaff E, et al.: Establishment of persistent Hepatitis C virus infection and replication in vitro. J Gen Virol 1997,78(Pt 10):2467-2476.View ArticlePubMedGoogle Scholar
- Song ZQ, Hao F, Minm F, et al.: Hepatitis C virus infection of human hepatoma cell line 7721 in vitro. World J Gastroenterol 2001,7(5):685-689.PubMed CentralPubMedGoogle Scholar
- Harlow E, Lane D: Using antibodies: A laboratory manual. Cold Spring Harbor Laboratory Press; 1999.Google Scholar
- Deleersnyder V, Pillez A, Wychowski C, et al.: Formation of native Hepatitis C virus glycoprotein complexes. J Virol 1997,71(1):697-704.PubMed CentralPubMedGoogle Scholar
- El-Awady MK, Tabll AA, Yousif H, et al.: Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of Hepatitis C virus. Vaccine 2010,28(52):8338-8344. 10.1016/j.vaccine.2009.11.059View ArticlePubMedGoogle Scholar
- Zhang J, Randall G, Higginbottom A, et al.: CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection. J Virol 2004,78(3):1448-1455. 10.1128/JVI.78.3.1448-1455.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Diedrich G: How does Hepatitis C virus enter cells? FEBS J 2006,273(17):3871-3885. 10.1111/j.1742-4658.2006.05379.xView ArticlePubMedGoogle Scholar
- Choukhi A, Pillez A, Drobecq H, et al.: Characterization of aggregates of Hepatitis C virus glycoproteins. J Gen Virol 1999,80(12):3099-3107.View ArticlePubMedGoogle Scholar
- Triyatni M, Saunier B, Maruvada P, et al.: Interaction of Hepatitis C virus-like particles and cells: A model system for studying viral binding and entry. J Virol 2002,76(18):9335-9344. 10.1128/JVI.76.18.9335-9344.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Nielsen SU, Bassendine MF, Burt AD, et al.: Characterization of the genome and structural proteins of Hepatitis C virus resolved from infected human liver. J Gen Virol 2004,85(6):1497-1507. 10.1099/vir.0.79967-0PubMed CentralView ArticlePubMedGoogle Scholar
- Yuk CS, Lee HK, Kim HT, et al.: Development and evaluation of a protein microarray chip for diagnosis of Hepatitis C virus. Biotechnol Lett 2004,26(20):1563-1568.View ArticlePubMedGoogle Scholar
- Buck M: Direct infection and replication of naturally occurring Hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. PLoS One 2008,3(7):e2660. 10.1371/journal.pone.0002660PubMed CentralView ArticlePubMedGoogle Scholar
- Bartenschlager R, Lohmann V: Replication of Hepatitis C virus. J Gen Virol 2000, 81: 1631-1648.View ArticlePubMedGoogle Scholar
- Langman RE: Molecular economy and antibody function: The evolution of a protection. Int J Clin Lab Res 1992,22(2):63-68. 10.1007/BF02591398View ArticlePubMedGoogle Scholar
- Hsu M, Zhang J, Flint M, et al.: Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003,100(12):7271-7276. 10.1073/pnas.0832180100PubMed CentralView ArticlePubMedGoogle Scholar
- Meunier JC, Engle RE, Faulk K, et al.: Evidence for crossgenotype neutralization of Hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein c1. Proc Natl Acad Sci USA 2005,102(12):4560-4565. 10.1073/pnas.0501275102PubMed CentralView ArticlePubMedGoogle Scholar
- Von Hahn T, Yoon JC, Alter H, et al.: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007,132(2):667-678. 10.1053/j.gastro.2006.12.008View ArticlePubMedGoogle Scholar
- Stamataki Z, Coates S, Evans MJ, et al.: Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007,25(45):7773-7784. 10.1016/j.vaccine.2007.08.053View ArticlePubMedGoogle Scholar
- Molina S, Castet V, Fournier-Wirth C, et al.: The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by Hepatitis C virus. J Hepatol 2007,46(3):411-419. 10.1016/j.jhep.2006.09.024View ArticlePubMedGoogle Scholar
- Guha C, Lee SW, Chowdhury NR, et al.: Cell culture models and animal models of viral hepatitis. Part II: Hepatitis C. Lab Anim (NY) 2005,34(2):39-47. 10.1038/laban0205-39View ArticleGoogle Scholar
- Rumin S, Berthillon P, Tanaka E, et al.: Dynamic analysis of Hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol 1999,80(11):3007-3018.View ArticlePubMedGoogle Scholar
- Zhu LX, Liu J, Ye Y, et al.: A candidate DNA vaccine elicits hcv specific humoral and cellular immune responses. World J Gastroenterol 2004,10(17):2488-2492.PubMed CentralView ArticlePubMedGoogle Scholar
- Keck ZY, Machida K, Lai MM, et al.: Therapeutic control of Hepatitis C virus: The role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol 2008, 317: 1-38. 10.1007/978-3-540-72146-8_1PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.